Resources
 
KNOWLEDGE CENTER

Operational Similarities and Differences : USA VS EU

Given the globalization of the biopharma industry, consorting the drug regulatory environs of the United States of America (USA) and European Union (EU) are getting more and more important to fasten the development of new curatives.



Considerations in RBM Implementation

In this 5th Edition of Applied Clinical Trials' eBook on Risk-Based Monitoring in Clinical Trials, articles cover the advances that have been made in RBM since guidances' released in 2013. How is pharma implementing RBM - is it more remote, centralized or a combination? Read the article by Dr. Ashok Ghone, Vice-President, Global Services at MakroCare:Considerations in RBM Implementation



CER : new MEDDEV 2.7.1 REV 4: Why is This More Complex Now

In July’2016, the EU has published Rev.4 of MEDDE V2.7.1 on clinical Evaluation for medica l devices.The new guidance document describes the requirement in a more detailed



Have Questions? Need Info/Quotes?